The role of E and N-cadherin in the postoperative course of gonadotroph pituitary tumours

Endocrine. 2018 Nov;62(2):351-360. doi: 10.1007/s12020-018-1679-0. Epub 2018 Jul 26.

Abstract

Purpose: Gonadotroph tumours are the most abundant of the clinically silent pituitary tumours. There is a lack of reliable prognostic markers predicting their clinical course. Our aim was to determine the level of E-cadherin and N-cadherin in a cohort of clinically silent gonadotroph pituitary tumours, and compare them to the rate of reintervention.

Methods: Tumour tissue from primary surgery was retrospectively investigated and compared with clinical data. Immunohistochemical (N = 105) and real time-qPCR (N = 85) analyses for the levels of N-cadherin and the extra- and intracellular domains of E-cadherin were performed. The immunoreactive scores (IRS) and mRNA relative quantity were compared to the rate of reintervention.

Results: The tumours presented a high IRS for N-cadherin (Median 12 (IQR 12-12)) and almost no immunoreactivity for the extracellular domain of E-cadherin (Median 0 (IQR 0-0)). The membranous staining for the intracellular domain of E-cadherin varied (Median 6 (IQR 4-6). Reduced membranous expression of the intracellular domain of E-cadherin was associated with nuclear presence of the same domain. Nuclear staining for the intracellular domain of E-cadherin was associated with a lower rate of reintervention (p = 0.01).

Conclusion: We found that silent gonadotroph tumours presented high IRS for N-cadherin and low IRS for the extracellular domain of E-cadherin. A substantial proportion of the tumours presented nuclear staining for the intracellular domain of E-cadherin, accompanied by a reduced membranous expression of the intracellular domain of E-cadherin. Absence of nuclear staining for the intracellular domain of E-cadherin served as an independent predictor of reintervention.

Keywords: Aggressiveness; Cadherin; EMT; Gonadotroph pituitary tumours; PitNET; Pituitary adenomas.

Publication types

  • Comparative Study

MeSH terms

  • Adenoma / diagnosis*
  • Adenoma / pathology
  • Adenoma / surgery*
  • Aged
  • Antigens, CD / physiology*
  • Biomarkers, Tumor / physiology
  • Cadherins / physiology*
  • Cohort Studies
  • Female
  • Gonadotrophs / pathology
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Pituitary Neoplasms / diagnosis*
  • Pituitary Neoplasms / pathology
  • Pituitary Neoplasms / surgery*
  • Postoperative Period
  • Prognosis
  • Retrospective Studies
  • Reverse Transcriptase Polymerase Chain Reaction
  • Treatment Outcome

Substances

  • Antigens, CD
  • Biomarkers, Tumor
  • CDH1 protein, human
  • CDH2 protein, human
  • Cadherins